AAIC
Arlington Asset Investment Corp.
stock NYSE

My AI Slop Analysis:
**\[mm\]** INMB — the zombie Alzheimer's play with a bladder full of shorts and a catalyst tomorrow

Zero-revenue clinical biotech. Flagship Alzheimer's drug — XPro1595 — failed its Phase 2 primary cognitive endpoint last June and the stock fell 60% in one premarket session. All-time high was $30.37 in September 2021, it's $1.94 today, down 93.6% from peak. So why is this corpse on the radar? Because their next data presentation is tomorrow — literally July 12 at the Alzheimer's Association International Conference in London — and 15.5% of the float is sitting short on this thing.

The Phase 2 trial enrolled 200 patients, missed the primary cognitive endpoint in the full population, and survived on a pre-specified 100-patient inflammatory biomarker subgroup where the benefit was real but modest — effect size 0.27 on cognition. That's the skeleton they're now building a Phase 2b/3 registrational trial on. FDA gave them Fast Track in May. What they're presenting tomorrow is MRI biomarker data showing XPro significantly moved white matter myelin markers in the brain: p=0.003 in the full 200-patient cohort, p=0.010 in the enriched 100-patient group. That's a biologically interesting signal. It is emphatically not the same as showing the drug helps people with Alzheimer's think better.

The thing that makes this management team permanently suspect: on the exact same day they announced the Phase 2 miss, they also closed a $19 million stock offering at $6.30 per share. The stock was about to fall 60%. Whether that timing was legal or sloppy or both, the market has not forgotten it. The founder CEO stepped out afterward. In two full years of tracking insider filings — before the trial miss and after — not one person running this company has put personal cash into the stock. Not one open-market buy. Grants, yes. Their own money? Zero.

Financials: $21.4 million cash, $1.5 million debt, burning about $3.4 million per quarter — roughly 19 months of runway. Enterprise value is $31.7 million on a $51.6 million market cap, meaning you're paying about $30 million above the cash pile for a subgroup-only Alzheimer's thesis and a cell therapy pipeline targeting an FDA filing in Q4 2026 for a rare skin disease.

The short side is crowded enough to make this interesting: 15.5% of the float short, covering in roughly five days. The stock has already run 78% off its 52-week low of $1.09 ahead of tomorrow's catalyst. The retail crowd hasn't piled in yet — minimal online chatter about this one — which is mildly encouraging for a squeeze setup.

Hard pass on conviction. The all-time high is 15.7x above current price — this is a fallen soldier with massive overhead. No insider conviction whatsoever. Phase 2b/3 isn't funded. The AAIC presentation tomorrow is a binary event on a stock that already bounced 78% off the bottom. If you're scalping, you needed to be in before today. If you want a real entry point, wait for a funded Phase 2b/3 design or a partnership announcement. Those would be genuinely new information. Slide decks at academic conferences rarely are.

INMB upcoming presentation at AAIC London 12/07

My AI Slop Analysis:
**\[mm\]** INMB — the zombie Alzheimer's play with a bladder full of shorts and a catalyst tomorrow

Zero-revenue clinical biotech. Flagship Alzheimer's drug — XPro1595 — failed its Phase 2 primary cognitive endpoint last June and the stock fell 60% in one premarket session. All-time high was $30.37 in September 2021, it's $1.94 today, down 93.6% from peak. So why is this corpse on the radar? Because their next data presentation is tomorrow — literally July 12 at the Alzheimer's Association International Conference in London — and 15.5% of the float is sitting short on this thing.

The Phase 2 trial enrolled 200 patients, missed the primary cognitive endpoint in the full population, and survived on a pre-specified 100-patient inflammatory biomarker subgroup where the benefit was real but modest — effect size 0.27 on cognition. That's the skeleton they're now building a Phase 2b/3 registrational trial on. FDA gave them Fast Track in May. What they're presenting tomorrow is MRI biomarker data showing XPro significantly moved white matter myelin markers in the brain: p=0.003 in the full 200-patient cohort, p=0.010 in the enriched 100-patient group. That's a biologically interesting signal. It is emphatically not the same as showing the drug helps people with Alzheimer's think better.

The thing that makes this management team permanently suspect: on the exact same day they announced the Phase 2 miss, they also closed a $19 million stock offering at $6.30 per share. The stock was about to fall 60%. Whether that timing was legal or sloppy or both, the market has not forgotten it. The founder CEO stepped out afterward. In two full years of tracking insider filings — before the trial miss and after — not one person running this company has put personal cash into the stock. Not one open-market buy. Grants, yes. Their own money? Zero.

Financials: $21.4 million cash, $1.5 million debt, burning about $3.4 million per quarter — roughly 19 months of runway. Enterprise value is $31.7 million on a $51.6 million market cap, meaning you're paying about $30 million above the cash pile for a subgroup-only Alzheimer's thesis and a cell therapy pipeline targeting an FDA filing in Q4 2026 for a rare skin disease.

The short side is crowded enough to make this interesting: 15.5% of the float short, covering in roughly five days. The stock has already run 78% off its 52-week low of $1.09 ahead of tomorrow's catalyst. The retail crowd hasn't piled in yet — minimal online chatter about this one — which is mildly encouraging for a squeeze setup.

Hard pass on conviction. The all-time high is 15.7x above current price — this is a fallen soldier with massive overhead. No insider conviction whatsoever. Phase 2b/3 isn't funded. The AAIC presentation tomorrow is a binary event on a stock that already bounced 78% off the bottom. If you're scalping, you needed to be in before today. If you want a real entry point, wait for a funded Phase 2b/3 design or a partnership announcement. Those would be genuinely new information. Slide decks at academic conferences rarely are.

INMB upcoming presentation at AAIC London 12/07